Asia Pacific Automated and Closed Cell Therapy Processing Systems Market By type (stem cell therapy, and non-stem cell therapy), By workflow (separation, expansion, apheresis, fill-finish, cryopreservation and others), By scale (Pre-commercial/R&D Scale and Commercial Scale), By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Asia Pacific Automated and Closed Cell Therapy Processing Systems Market
Market Report Description
The Asia Pacific Automated And Closed Cell Therapy Processing Systems Market would witness market growth of 21.9% CAGR during the forecast period (2021-2027).
There has been an increase in clinical trials regarding advanced therapies in the past few years, which is estimated to surge the demand for advanced & automated technologies to get high yield and throughput. Along with that, these systems would allow constant supervision of controlled therapy processing that is being performed for the development of the latest therapeutic platforms.
The growing requirement for various healthcare devices, systems, and medicines across various developing nations of the region like India and China would support the regional growth of the automated and closed cell therapy processing systems market over the forecast period. Along with that, the rise in investments by various government institutions and pharmaceutical companies to develop new solutions and medication would surge the growth of the regional market.
There is a rise in the prevalence of numerous chronic diseases that use cell therapies for the treatment. As the regional healthcare sector is becoming stronger, the demand for these systems would increase in the region.
The China market dominated the Asia Pacific Automated and Closed Cell Therapy Processing Systems Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $146.2 million by 2027. The Japan market is exhibiting a CAGR of 21.2% during (2021 - 2027). Additionally, the India market would experience CAGR of 22.5% during (2021 - 2027).
Based on type, the market is segmented into stem cell therapy, and non-stem cell therapy. Based on workflow, the market is segmented into separation, expansion, apheresis, fill-finish, cryopreservation and others. Based on scale, the market is segmented into Pre-commercial/R&D Scale and Commercial Scale.Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Lonza Group AG, Terumo Corporation, Cytiva (Danaher Corporation), Thermo Fisher Scientific, Inc., Miltenyi Biotec B.V. & Co. KG, Thermogenesis Holdings, Inc., Cellares Inc., Biospherix ltd., Sartorius AG, and Fresenius SE & Co. KGaA.
Scope of the Study
Market Segments Covered in the Report:
- Stem Cell Therapy
- Non-Stem Cell Therapy
- Pre-commercial/R&D Scale
- Commercial Scale
- South Korea
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Lonza Group AG
- Terumo Corporation
- Cytiva (Danaher Corporation)
- Thermo Fisher Scientific, Inc.
- Miltenyi Biotec B.V. & Co. KG
- Thermogenesis Holdings, Inc.
- Cellares Inc.
- Biospherix ltd.
- Sartorius AG
- Fresenius SE & Co. KGaA
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free